Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of TO-210 in Acne Vulgaris
jRCT2031250481Phase 3Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing TO-210 arm with Placebo arm (2 arms). Primary endpoint: Percentage change from baseline in total lesion count at Week 12 on the face. Started Nov 2025; status: completed.
02
Drugs
tapinarof
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on jRCT2031250481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250481.